Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018

Product Code:
596201197
Publication Date:
April 2018
Format:
PowerPoint
Price:
$5,345

Market barriers affect a fifth of oral diabetes treatment prescriptions in Europe. Is your brand losing out?

Market barriers affect over a fifth of all oral type 2 diabetes mellitus (T2DM) prescriptions in Europe, and certain brands are losing out on market share big time. Is it yours? Find out what’s driving share gains, and what your brand can do to level the playing field in Market Access Impact: Type 2 Diabetes Mellitus (Orals) (EU5) [2018].

Based on a survey of 150 European diabetologists from the leading EU5 markets (France, Germany, Italy, Spain, and the UK), the report covers 9 major oral therapies from AstraZeneca, Eli Lilly, Boehringer Ingelheim, Janssen Cilag, Merck Sharp & Dohme, and Takeda. Handy graphs and charts reveal which  of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Interested in the US market? Click here to see the US Edition.

Request sample pages

Top Takeaways

  • Barriers affect just over a fifth of all prescriptions. Small, perhaps, but brands are still losing out on market share opportunities because of them. is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
  • One brand sees a robust share increase. Is this lead too big for the chasing pack to overcome? Is your brand leading, or are you in the chasing pack?
  • Two brands see a significant loss. Could market share losses be due to low prescribing rates, or is some other market dynamic at play? And perhaps most importantly, can this be prevented?
  • Eliminating barriers would have limited impact. Due to the overall barrier impact being 20 percent, eliminating barriers would have limited impact on market share performance.
  • Perception is a huge problem. Across all but one of the brands, a certain proportion of physicians have never heard of the treatment. Could improved physician education be the key to better market shares?

Insight into 9 Oral Type 2 Diabetes Mellitus Treatments

  • Forxiga (dapagliflozin; AstraZeneca)
  • Glyxambi (empagliflozin/linagliptin; Eli Lilly/Boehringer Ingelheim)
  • Invokana (canagliflozin; Janssen Cilag)
  • Januvia (sitagliptin; Merck Sharp & Dohme)
  • Jardiance (empagliflozin; Eli Lilly/Boehringer Ingelheim)
  • Onglyza (saxagliptin; AstraZeneca)
  • Qtern (saxagliptin/dapagliflozin; AstraZeneca)
  • Trajenta (linagliptin; Eli Lilly/Boehringer Ingelheim)
  • Vipidia (alogliptin; Takeda)

Exploring Important Market Access Issues

Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) explores key issues affecting type 2 diabetes mellitus drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 diabetologists and primary care physicians—30 from each EU5 country (France, Italy, Germany, Spain, UK)chosen from the largest community of validated physicians in the world. All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with type 2 diabetes mellitus in total in the last month

We conducted the survey between April 5-10, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved